Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.47 |
| ▸ | RARG | P13631 | 12/20 | 0.47 |
| ▸ | RARA | P10276 | 11/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.47 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 10/20 | 0.47 |
| ▸ | RXRB | P28702 | 6/20 | 0.47 |
| ▸ | RXRG | P48443 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555814 | 0.87 | RARB (0.46) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL14392801 | 0.86 | RARB (0.50) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL14008397 | 0.85 | MAPT (0.44) | RARBRARGRXRARXRBRXRG | |
| SCHEMBL14106675 | 0.83 | KDM4E (0.42) | ALDH1A1TSHRKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL17586732 | 0.82 | RARB (0.43) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL10272144 | 0.80 | ATM (0.42) | CYP26A1CYP26B1CYP3A4ALDH1A1TSHR | |
| SCHEMBL10222462 | 0.80 | RXRA (0.34) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL14172876 | 0.79 | GSK3B (0.46) | RARBRARGCYP26A1CYP26B1RXRA | |
| SCHEMBL14008398 | 0.76 | RARA (0.34) | RARBRARGRARARXRARXRB | |
| SCHEMBL1298043 | 0.75 | MEN1 (0.45) | RARBRARGRARACYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9358225-B2 | Method for treating neurodegeneration using a p38MAPK inhibitor | BACH PHARMA, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140303212-A1 | METHOD FOR TREATING NEURODEGENERATION USING A p38MAPK INHIBITOR | Occhiuti & Rohlicek LLP | 2014-10-09 | — | — | US | disclosed |
| WO-2014145472-A2 | A METHOD FOR TREATING NEURODEGENERATION USING A P38MAPK INHIBITOR | WONG PAUL K Y (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2011-11-03 | — | — | US | disclosed |
| EP-2344454-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | Queensland University Of Technology (AU) | 2011-07-20 | — | — | EP | disclosed |
| US-20110027351-A1 | LIPOSOMAL FORMULATIONS COMPRISING AN AMPHIPATHIC WEAK BASE LIKE TEMPAMINE FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-02-03 | — | — | US | disclosed |
| WO-2010037172-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2010-04-08 | — | — | WO | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080063702-A1 | Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2008-03-13 | — | — | US | disclosed |
| EP-1793805-A1 | LIPOSOMAL FORMULATIONS COMPRISING AN AMPHIPATHIC WEAK BASE LIKE TEMPAMINE FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006027785-A1 | LIPOSOMAL FORMULATIONS COMPRISING AN AMPHIPATHIC WEAK BASE LIKE TEMPAMINE FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | RARB 1787/4885RARG 2165/4885RARA 2426/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | RARB 701/4885RARG 820/4885RARA 647/4885 |
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | NQO1, NFE2L2, GPX4 | RARB 1791/4885RARG 1437/4885RARA 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.